Endocrinology Medical News about management of hypertension;Perindopril;Amlodipine

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: Results from the STRONG prospective, observational, multicenter study
American Journal of Cardiovascular Drugs, 06/03/09

Bahl VK et al. – Fixed combination perindopril/amlodipine is an effective and well tolerated antihypertensive treatment, with an excellent rate of treatment adherence in the clinical setting. Fixed combination perindopril/amlodipine will be useful in management of hypertension in primary healthcare, with a positive impact on treatment adherence.

Methods

Study of efficacy and tolerability of fixed combination of perindopril and amlodipine in the clinical setting
Design: prospective, observational, multicenter trial – the STRONG study (SafeTy & efficacy analysis of coveRsyl amlodipine in uncOntrolled and Newly diaGnosed hypertension)
Setting: naturalistic, real-world, clinic-based, outpatient study of 336 general practitioners/primary care physicians in 65 cities in India
Subjects: adults age 40-70 yrs with newly diagnosed/untreated stage 2 hypertension (BP >=160/100 mmHg), hypertension uncontrolled with monotherapy (BP >140/90 mmHg), or hypertension inadequately managed with another combination therapy
Intervention: Fixed combination perindopril 4 mg/amlodipine 5 mg once daily for 60 days
Primary outcomes: mean change in BP from baseline and proportion of pts achieving adequate BP control (<=140/90 mmHg, or <=130/80 mmHg in pts with diabetes mellitus) in intent-to-treat (ITT) population
Secondary analyses: incidence of adverse events (ITT) and treatment adherence rate (completers)

Results

ITT population of 1250 pts total: 32.6% with newly diagnosed hypertension; 40.5% with hypertension uncontrolled with monotherapy; and 26.9% with hypertension inadequately managed with another combination therapy
Mean SBP/DBP decreased significantly from baseline over 60 days
Target BP in 66.1% of pts in total population, 68.3% of untreated pts, 68.4% of pts uncontrolled with monotherapy, and 59.9% of pts inadequately managed with combination therapy
In 161 pts with SBP >180 mmHg at baseline, BP reduced by day 60
Fixed combination was safe and well tolerated
All 1175 pts completing 60-day study (94%) adhered to treatment regimen

<< Previous
Effects of a dairy product (pecorino cheese) naturally rich in...

Next >>
Residual cardiovascular risk in treated hypertension and...